Cargando…
15. Real-World Changes in Clostridioides difficile infection (CDI) Treatment Utilization and Clinical Outcomes Associated with Updated 2017 IDSA Guidelines among Medicare Beneficiaries in the U.S
BACKGROUND: The 2017 IDSA CDI guideline update phased out metronidazole (MTZ) and recommended vancomycin (VAN) or fidaxomicin (FDX) for first-line use. This study examined changes in CDI antibiotic use and clinical outcomes among Medicare beneficiaries with CDI pre- vs. post- the guideline update. M...
Autores principales: | Dubberke, Erik R, Puckett, Justin T, Obi, Engels N, Kamal-Bahl, Sachin, Desai, Kaushal, Stuart, Bruce, Doshi, Jalpa A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643958/ http://dx.doi.org/10.1093/ofid/ofab466.015 |
Ejemplares similares
-
Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes
por: Dubberke, Erik R, et al.
Publicado: (2022) -
678. Changes in the Clostridioides difficile Infection (CDI) Treatment Pattern Pre-Post Clinical Guideline Update in 2021 and Variations across Hospitals
por: Dubberke, Erik R, et al.
Publicado: (2023) -
Predictability of Prescription Drug Expenditures for Medicare Beneficiaries
por: Wrobel, Marian V., et al.
Publicado: (2003) -
Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021) -
Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries
por: Doshi, Jalpa A, et al.
Publicado: (2021)